As Introduced

132nd General Assembly Regular Session 2017-2018

H. B. No. 601

1

3

18

Representative Ginter

A BILL

addiction treatment.

To amend sections 4723.52, 4729.45, 4729.553,

BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF OHIO:

4730.56, and 4731.83 of the Revised Code regarding administration of drugs for drug

Section 1. That sections 4723.52, 4729.45, 4729.553,	5
4730.56, and 4731.83 of the Revised Code be amended to read as	6
follows:	7
Sec. 4723.52. (A) As used in this section:	8
(1) "Community addiction services provider" has the same	9
meaning as in section 5119.01 of the Revised Code.	10
(2) "Medication-assisted treatment" has the same meaning	11
as in section 340.01 of the Revised Code.	12
(B) An advanced practice registered nurse shall comply	13
with section 3715.08 of the Revised Code and rules adopted under	14
section 4723.51 of the Revised Code when treating a patient for	15
addiction with medication-assisted treatment or proposing to	16
initiate such treatment.	17

(C) An advanced practice registered nurse who fails to

H. B. No. 601 Page 2 As Introduced

comply with this section shall treat not more than thirty	19
patients at any one time with medication-assisted treatment even	20
if the facility or location at which the treatment is provided	21
is either of the following:	22
(1) Exempted by divisions (B)(2)(a)(i) to (d)(iv) and	23
(vii) of section 4729.553 of the Revised Code from being	24
required to possess a category III terminal distributor of	25
dangerous drugs license with an office-based opioid treatment	26
classification;	27
(2) A community addiction services provider that provides	28
alcohol and drug addiction services that are certified by the	29
department of mental health and addiction services under section	30
5119.36 of the Revised Code.	31
Sec. 4729.45. (A) As used in this section, "physician"	32
means an individual authorized under Chapter 4731. of the	33
Revised Code to practice medicine and surgery or osteopathic	34
medicine and surgery.	35
(B)(1) Subject to division (C) of this section, a	36
pharmacist licensed under this chapter may administer by	37
injection any of the following drugs as long as the drug that is	38
to be administered has been prescribed by a physician and the	39
individual to whom the drug was prescribed has an ongoing	40
physician-patient relationship with the physician:	41
(a) An opioid antagonist A drug used for treatment of drug	42
addiction and administered in a long-acting or extended-release	43
form;	44
(b) An antipsychotic drug administered in a long-acting or	45
extended-release form;	46
	. –
(c) Hydroxyprogesterone caproate;	47

H. B. No. 601
As Introduced

(d) Medroxyprogesterone acetate;	48
(e) Cobalamin.	49
(2) As part of engaging in the administration of drugs by	50
injection pursuant to this section, a pharmacist may administer	51
epinephrine or diphenhydramine, or both, to an individual in an	52
emergency situation resulting from an adverse reaction to a drug	53
administered by the pharmacist.	54
(C) To be authorized to administer drugs pursuant to this	55
section, a pharmacist must do all of the following:	56
(1) Successfully complete a course in the administration	57
of drugs that satisfies the requirements established by the	58
state board of pharmacy in rules adopted under division (H)(1)	59
(a) of this section;	60
(2) Receive and maintain certification to perform basic	61
life-support procedures by successfully completing a basic life-	62
support training course certified by the American red cross or	63
American heart association;	64
(3) Practice in accordance with a protocol that meets the	65
requirements of division (F) of this section.	66
(D) Each time a pharmacist administers a drug pursuant to	67
this section, the pharmacist shall do all of the following:	68
(1) Obtain permission in accordance with the procedures	69
specified in rules adopted under division (H) of this section	70
and comply with the following requirements:	71
(a) Except as provided in division (D)(1)(c) of this	72
section, for each drug administered by a pharmacist to an	73
individual who is eighteen years of age or older, the pharmacist	74
shall obtain permission from the individual.	75

(b) For each drug administered by a pharmacist to an	76
individual who is under eighteen years of age, the pharmacist	77
shall obtain permission from the individual's parent or other	78
person having care or charge of the individual.	79
(c) For each drug administered by a pharmacist to an	80
individual who lacks the capacity to make informed health care	81
decisions, the pharmacist shall obtain permission from the	82
person authorized to make such decisions on the individual's	83
behalf.	84
(2) In the case of an opioid antagonist a drug described	85
in division (B) $\underline{(1)(a)}$ of this section, obtain in accordance with	86
division (E) of this section test results indicating that it is	87
appropriate to administer the drug to the individual if either	88
of the following is to be administered:	89
(a) The initial dose of the drug;	90
(b) Any subsequent dose, if the administration occurs more	91
than thirty days after the previous dose of the drug was	92
administered.	93
(3) Observe the individual to whom the drug is	94
administered to determine whether the individual has an adverse	95
reaction to the drug;	96
(4) Notify the physician who prescribed the drug that the	97
drug has been administered to the individual.	98
(E) A pharmacist may obtain the test results described in	99
division (D)(2) of this section in either of the following ways:	100
(1) From the physician;	101
(2) By ordering blood and urine tests for the individual	102
to whom the opioid antagonist drug is to be administered.	103

If a pharmacist orders blood and urine tests, the	104
pharmacist shall evaluate the results of the tests to determine	105
whether they indicate that it is appropriate to administer the	106
opioid antagonist drug. A pharmacist's authority to evaluate	107
test results under this division does not authorize the	108
pharmacist to make a diagnosis.	109
(F) All of the following apply with respect to the	110
protocol required by division (C)(3) of this section:	111
(1) The protocol must be established by a physician who	112
has a scope of practice that includes treatment of the condition	113
for which the individual has been prescribed the drug to be	114
administered.	115
(2) The protocol must satisfy the requirements established	116
in rules adopted under division (H)(1)(b) of this section.	117
(3) The protocol must do all of the following:	118
(a) Specify a definitive set of treatment guidelines;	119
(b) Specify the locations at which a pharmacist may engage	120
in the administration of drugs pursuant to this section;	121
(c) Include provisions for implementing the requirements	122
of division (D) of this section, including for purposes of	123
division (D)(3) of this section provisions specifying the length	124
of time and location at which a pharmacist must observe an	125
individual who receives a drug to determine whether the	126
individual has an adverse reaction to the drug;	127
(d) Specify procedures to be followed by a pharmacist when	128
administering epinephrine, diphenhydramine, or both, to an	129
individual who has an adverse reaction to a drug administered by	130
the pharmacist.	131

(G) A pharmacist shall not do either of the following:	132
(1) Engage in the administration of drugs pursuant to this	133
section unless the requirements of division (C) of this section	134
have been met;	135
(2) Delegate to any person the pharmacist's authority to	136
engage in the administration of drugs pursuant to this section.	137
(H)(1) The state board of pharmacy shall adopt rules to	138
implement this section. The rules shall be adopted in accordance	139
with Chapter 119. of the Revised Code and include all of the	140
following:	141
(a) Requirements for courses in administration of drugs;	142
(b) Requirements for protocols to be followed by	143
pharmacists in administering drugs pursuant to this section;	144
(c) Procedures to be followed by a pharmacist in obtaining	145
permission to administer a drug to an individual.	146
(2) The board shall consult with the state medical board	147
before adopting rules regarding requirements for protocols under	148
this section.	149
Sec. 4729.553. (A) As used in this section:	150
(1) "Advanced practice registered nurse" has the same	151
meaning as in section 4723.01 of the Revised Code.	152
(2) "Controlled substance" has the same meaning as in	153
section 3719.01 of the Revised Code.	154
$\frac{(2)}{(3)}$ "Hospital" means a hospital registered with the	155
department of health under section 3701.07 of the Revised Code.	156
(3) _(4) _"Office-based opioid treatment" means the	157
treatment of opioid dependence or addiction using a controlled	158

H. B. No. 601 Page 7
As Introduced

substance.	159
(5) "Physician" means an individual who is authorized	160
under Chapter 4731. of the Revised Code to practice medicine and	161
surgery or osteopathic medicine and surgery.	162
(6) "Physician assistant" means an individual who is	163
licensed under Chapter 4730. of the Revised Code.	164
(B)(1) Except as provided in division (B)(2) of this	165
section, no person shall knowingly operate a facility, clinic,	166
or other location where a prescriber provides office-based	167
opioid treatment to more than thirty patients or that meets any	168
other identifying criteria established in rules adopted under	169
division (G) of this section without holding a category III	170
terminal distributor of dangerous drugs license with an office-	171
based opioid treatment classification.	172
(2) (a) Division (B) (1) of this section does not apply to	173
any of the following:	174
(a)—(i)_A hospital;	175
(b) (ii) A facility for the treatment of opioid dependence	176
or addiction that is operated by a hospital;	177
(c) (iii) A physician practice owned or controlled, in	178
whole or in part, by a hospital or by an entity that owns or	179
controls, in whole or in part, one or more hospitals;	180
(d) (iv) A facility that conducts only clinical research	181
and uses controlled substances in studies approved by a	182
hospital-based institutional review board or an institutional	183
review board that is accredited by the association for the	184
accreditation of human research protection programs, inc.;	185
(e) (v) A facility that holds a category III terminal	186

H. B. No. 601 Page 8
As Introduced

distributor of dangerous drugs license in accordance with	187
section 4729.54 of the Revised Code for the purpose of treating	188
drug dependence or addiction as part of an opioid treatment	189
program and is the subject of a current, valid certification	190
from the substance abuse and mental health services	191
administration of the United States department of health and	192
human services pursuant to 42 C.F.R. 8.11;	193
(f) (vi) A program or facility that is licensed or	194
certified by the department of mental health and addiction	195
services under Chapter 5119. of the Revised Code;	196
(vii) A place in which patients are treated for opioid	197
dependence or addiction by direct administration by a physician,	198
physician assistant, or advanced practice registered nurse of	199
drugs that are used for addiction treatment and are not	200
dispensed to patients for self-administration.	201
(b) Patients who receive treatment for opioid drug	202
dependence or addiction by direct administration of a drug by a	203
physician, physician assistant, or advanced practice registered	204
nurse shall not be included in determining whether more than	205
thirty patients are being provided office-based opioid treatment	206
in a particular facility, clinic, or other location that is	207
subject to division (B)(1) of this section.	208
(C) To be eligible to receive a license as a category III	209
terminal distributor of dangerous drugs with an office-based	210
opioid treatment classification, an applicant shall submit	211
evidence satisfactory to the state board of pharmacy that the	212
applicant's office-based opioid treatment will be operated in	213
accordance with the requirements specified in division (D) of	214
this section and that the applicant meets any other applicable	215
requirements of this chapter.	216

If the board determines that an applicant meets all of the	217
requirements, the board shall issue to the applicant a license	218
as a category III terminal distributor of dangerous drugs with	219
an office-based opioid treatment classification.	220
(D) The holder of a category III terminal distributor	221
license with an office-based opioid treatment classification	222
shall do all of the following:	223
(1) Be in control of a facility that is owned and operated	224
solely by one or more physicians authorized under Chapter 4731.	225
of the Revised Code to practice medicine and surgery or	226
osteopathic medicine and surgery, unless the state board of	227
pharmacy has exempted the holder from this requirement;	228
(2) Comply with the requirements for conducting office-	229
based opioid treatment, as established by the state medical	230
board in rules adopted under section 4731.056 of the Revised	231
Code;	232
(3) Require any person with ownership of the facility to	233
submit to a criminal records check in accordance with section	234
4776.02 of the Revised Code and send the results of the criminal	235
records check directly to the state board of pharmacy for review	236
and decision under section 4729.071 of the Revised Code;	237
(4) Require all employees of the facility to submit to a	238
criminal records check in accordance with section 4776.02 of the	239
Revised Code and ensure that no person is employed who has	240
previously been convicted of, or pleaded guilty to, either of	241
the following:	242
(a) A theft offense, described in division (K)(3) of	243
section 2913.01 of the Revised Code, that would constitute a	244
felony under the laws of this state, any other state, or the	245

H. B. No. 601	Page 10
As Introduced	

United States;	246
(b) A felony drug offense, as defined in section 2925.01	247
of the Revised Code.	248
(5) Maintain a list of each person with ownership of the	249
facility and notify the state board of pharmacy of any change to	250
that list.	251
(E) No person subject to licensure as a category III	252
terminal distributor of dangerous drugs with an office-based	253
opioid treatment classification shall knowingly fail to remain	254
in compliance with the requirements of division (D) of this	255
section and any other applicable requirements of this chapter.	256
(F) The state board of pharmacy may impose a fine of not	257
more than five thousand dollars on a person who violates	258
division (B) or (E) of this section. A separate fine may be	259
imposed for each day the violation continues. In imposing the	260
fine, the board's actions shall be taken in accordance with	261
Chapter 119. of the Revised Code.	262
(G) The state board of pharmacy shall adopt rules as it	263
considers necessary to implement and administer this section.	264
The rules shall be adopted in accordance with Chapter 119. of	265
the Revised Code.	266
Sec. 4730.56. (A) As used in this section:	267
(1) "Community addiction services provider" has the same	268
meaning as in section 5119.01 of the Revised Code.	269
(2) "Medication-assisted treatment" has the same meaning	270
as in section 340.01 of the Revised Code.	271
(B) A physician assistant shall comply with section	272
3715.08 of the Revised Code and rules adopted under section	273

H. B. No. 601 Page 11 As Introduced

4730.55 of the Revised Code when treating a patient with	274
medication-assisted treatment or proposing to initiate such	275
treatment.	276
(C) A physician assistant who fails to comply with this	277
section shall treat not more than thirty patients at any one	278
time with medication-assisted treatment even if the facility or	279
location at which the treatment is provided is either of the	280
following:	281
(1) Exempted by divisions (B)(2)(a)(i) to $\frac{(d)}{(i)}$ and	282
(vii) of section 4729.553 of the Revised Code from being	283
required to possess a category III terminal distributor of	284
dangerous drugs license with an office-based opioid treatment	285
classification;	286
(2) A community addiction services provider that provides	287
alcohol and drug addiction services that are certified by the	288
department of mental health and addiction services under section	289
5119.36 of the Revised Code.	290
Sec. 4731.83. (A) As used in this section:	291
(1) "Medication-assisted treatment" has the same meaning	292
as in section 340.01 of the Revised Code.	293
(2) "Physician" means an individual authorized by this	294
chapter to practice medicine and surgery or osteopathic medicine	295
and surgery.	296
(B) A physician shall comply with section 3715.08 of the	297
Revised Code and rules adopted under section 4731.056 of the	298
Revised Code when treating a patient with medication-assisted	299
treatment or proposing to initiate such treatment.	300
(C) A physician who fails to comply with this section	301

H. B. No. 601	Page 12
As Introduced	_

shall treat not more than thirty patients at any one time with	302
medication-assisted treatment even if the facility or location	
at which the treatment is provided is either of the following:	304
(1) Exempted by divisions (B)(2)(a)(i) to (d)(iv) and	305
(vii) of section 4729.553 of the Revised Code from being	306
required to possess a category III terminal distributor of	307
dangerous drugs license with an office-based opioid treatment	308
classification;	309
	0.1.0
(2) A community addiction services provider that provides	310
alcohol and drug addiction services that are certified by the	311
department of mental health and addiction services under section	312
5119.36 of the Revised Code.	313
Section 2. That existing sections 4723.52, 4729.45,	314
4729.553, 4730.56, and 4731.83 of the Revised Code are hereby	315
repealed.	316